Skip to main content

Advertisement

Table 5 Serum infliximab level and disease activity in three classes stratified on the basis of rheumatoid factor and anti-cyclic citrullinated peptide antibodies

From: High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study

  Low/low class (n = 53) Middle class (n = 183) High/high class (n = 71) p Value
Serum infliximab level, μg/ml
 Week 2 13.9 (12.0, 15.7) 13.2 (10.2, 16.3) 12.0 (9.5, 14.2) 0.0028
 Week 6 7.6 (4.5, 10.8) 7.1 (2.5, 10.0) 5.0 (1.6, 8.2) 0.0072
 Week 10 7.7 (3.9, 10.5) 6.3 (2.0, 10.3) 3.8 (1.5, 7.9) 0.0040
 Week 14 1.5 (0.6, 2.1) 0.7 (<0.1, 2.0) 0.4 (<0.1, 1.1) 0.0014
 Week 14, < 0.1/≥ 0.1 to < 0.1/≥ 1.0 13%/25%/62% 33%/25%/42% 32%/38%/30% 0.0015
DAS28-CRP
 Week 2 3.89 (3.09, 4.51) 3.90 (3.24, 4.52) 4.01 (3.34, 4.79) 0.2770
 Week 6 3.32 (2.78, 4.16) 3.42 (2.67, 4.22) 3.68 (2.96, 4.36) 0.2381
 Week 10 3.19 (2.57, 3.77) 3.24 (2.55, 4.12) 3.48 (2.67, 4.20) 0.3612
 Week 14 3.17 (2.49, 3.69) 3.53 (2.63, 4.36) 3.82 (2.62, 4.97) 0.0764
 Week 14, REM/LDA/MDA/HDA 17%/15%/51%/17% 15%/12%/40%/33% 18%/10%/31%/41% 0.1455
  1. Abbreviations: DAS28-CRP Disease Activity Score in 28 joints based on C-reactive protein, HDA High disease activity, LDA Low disease activity without clinical remission, MDA Moderate disease activity, REM Clinical remission
  2. Data are median (interquartile range) or number of patients (%). Cutoff values for DAS28-CRP were as follows: REM < 2.3, LDA ≥ 2.3 to < 2.7, MDA ≥ 2.7 to ≤ 4.1, HDA > 4.1 [22]. The Kruskal-Wallis test was used to evaluate the differences among three classes